Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IM 1240

Next Previous
X
Search
Drug Profile

IM 1240

Alternative Names: IM-1240

Latest Information Update: 05 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Purple Biotech
  • Class Antineoplastics; Immunotherapies; Trispecific antibodies
  • Mechanism of Action Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 05 Jun 2024 Purple Biotech announces intention to IND application to US FDA for Solid tumours in 2025
  • 21 Feb 2023 Preclinical trials in Solid tumours in Israel (Parenteral), before February 2023 (Purple Biotech pipeline, February 2023)
  • 31 Dec 2022 Purple Biotech has patents pending for IM 1240 in Australia, Brazil, Canada, China, Europe, Israel, India, Japan, the Republic of Korea, Mexico, USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top